Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

    ... of somatic mutations in myelodysplastic syndromes (MDS), the clinical relevance of variant allele frequency (VAF) for the ... genes in our training set of 219 patients with MDS or secondary acute myeloid leukemia with findings confirmed in a validation ...

    Research Article last updated 12/08/2015 - 1:04pm.

  2. Clinical Trials: What Are Phases, and What Happens in Each One?

    ... it’s the first time a drug has been used in someone with MDS. Frequently the drugs we use in a Phase 1 setting are ones that have been ... express purpose of these trials! Drug efficacy is actually a secondary aim in Phase 1 trials, though sometimes we are pleasantly surprised ...

    Interview last updated 11/16/2015 - 8:32am.

  3. 2014 Scholarships Awarded to Special Group of Young People

    ... Due to the alphabet starting with "A," the Aplastic Anemia & MDS International Foundation’s Debono scholarship was the first one people ... Thomas had to miss a year of school and had debilitating secondary issues post-transplant including two knee surgeries. Now it has ...

    Page last updated 10/22/2015 - 8:28am.

  4. Types of Research Articles Part I

    ... Library of Medicine. Research articles can be primary or secondary. A primary research article describes the design, methods, and results of a study. A secondary research article is a review of at least two primary research ...

    Page last updated 08/20/2015 - 12:50pm.

  5. 2015 Scholarships Awarded to Special Group of Young People

    ... aplastic anemia. Others have also been affected by PNH and MDS. They have survived difficult treatments for their disease and through ... However, after the transplant, this excellent student had secondary problems that slowed him down, but didn’t stop him. Thomas has had ...

    Page last updated 08/14/2015 - 3:36pm.

  6. The Revised International Prognostic Scoring System (IPSS-R) is not Predictive of Survival in Patients with Secondary Myelodysplastic Syndromes

    ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 05/26/2015 - 11:02am.

  7. Impact of the revised International Prognostic Scoring System cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndr

    ... in patients with myelodysplastic syndromes or secondary acute myeloid leukemia who were reported to the European Society for ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 03/02/2015 - 2:46pm.

  8. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms

    ... as a discovery tool in myelodysplastic syndromes (MDS) has led to the identification of a large number of novel mutations. ... and identification of a subset of ancestral and secondary molecular lesions. Chromosomal gains and losses have been ... phenocopy. In addition to the search for somatic defects in MDS, similar discovery studies have been also performed to identify germ line ...

    Research Article last updated 03/03/2015 - 1:30pm.

  9. Transplants in Myelodysplastic Syndromes

    ... an increase in the prevalence of de novo but also of secondary forms after prior chemotherapy or radiotherapy, ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 01/20/2015 - 1:10pm.

  10. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

    ... (AZA) failure in higher-risk myelodysplastic syndromes (MDS) is poor and new treatment options are needed. Erlotinib, an oral ... or 150mg/day (n=25) of Erlotinib orally after primary or secondary resistance to AZA treatment. Eighteen MDS and 12 AML patients were ...

    Research Article last updated 01/20/2015 - 1:14pm.